A Brazilian study suggests cannabidiol (CBD) may help ease autism symptoms in children and young adults. Researchers from the University of São Paulo reported that oral CBD led to improvements in social skills, fewer tantrums, and reduced aggression in participants. Presented at the 2025 European Congress of Psychiatry, the findings indicate CBD could complement traditional therapies, though experts urge larger trials to confirm results.
Interest in CBD arises from its role in supporting the body’s endocannabinoid system, which influences mood and stress. Unlike THC, CBD does not cause a high, making it a more acceptable option for neurological conditions beyond autism, such as epilepsy, while avoiding psychoactive effects.
The trial enrolled 276 participants aged five to 21 with autism spectrum disorder. Participants received CBD or a placebo, starting with a low dose and gradually increasing. Beyond social improvements, researchers observed moderate reductions in disruptive behavior, better sleep, and lower anxiety. They also cautioned about the variability in responses and the limited number of high-quality studies available for review, signaling the need for more rigorous research.
Autism affects an estimated one in 36 children in the United States, underscoring the potential impact of new treatment approaches. In Thailand, awareness of autism has grown, and families and clinicians are keen to understand how emerging therapies may fit with local medical practice. Thailand’s healthcare system continues to blend traditional and modern approaches, with a focus on evidence-based care.
Regulatory frameworks shape CBD’s availability. In the United States, medical cannabis is widely used in some contexts, while in other regions access remains restricted. Thailand has legalized medical cannabis, positioning the country to explore CBD’s potential in autism care, albeit alongside careful policy considerations.
Looking ahead, Thai families and healthcare professionals are watching developments with cautious optimism. The overarching message is clear: more robust research is essential to establish CBD’s long-term safety and effectiveness. Until then, families should discuss any CBD use with healthcare providers and continue relying on established treatment plans.
According to research from international institutions, ongoing studies aim to clarify how CBD works for autism and to identify which subgroups may benefit most. Data from leading universities and health organizations highlight the importance of standardized protocols and rigorous trial designs before wide clinical adoption.